摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Cyclohexylamine, dimer

中文名称
——
中文别名
——
英文名称
Cyclohexylamine, dimer
英文别名
——
Cyclohexylamine, dimer化学式
CAS
——
化学式
C13H21N
mdl
——
分子量
191.31
InChiKey
QQJLHUYLVJLVMF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.85
  • 拓扑面积:
    12.4
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'ÉTATS LIÉS AU STRESS
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2010137738A1
    公开(公告)日:2010-12-02
    The present invention provides a novel heterocyclic compound. A heterocyclic compound represented by general formula (1) wherein, R1 and R2, each independently represent hydrogen; a phenyl lower alkyl group that may have a substituent(s) selected from the group consisting of a lower alkyl group and the like on a benzene ring and/or a lower alkyl group; or a cyclo C3-C8 alkyl lower alkyl group; or the like; R3 represents a lower alkynyl group or the like; R4 represents a phenyl group that may have a substituent(s) selected from the group consisting of a 1,3,4-oxadiazolyl group that may have e.g., halogen or a heterocyclic group selected from pyridyl group and the like; the heterocyclic group may have at least one substituent(s) selected from a lower alkoxy group and the like or a salt thereof.
    本发明提供了一种新颖的杂环化合物。一种由通式(1)表示的杂环化合物,其中,R1和R2分别独立表示氢;苯基较低烷基基团,可能在苯环和/或较低烷基基团上具有从较低烷基基团等组成的取代基;或环C3-C8烷基较低烷基基团;或类似物;R3表示较低炔基基团或类似物;R4表示可能具有从1,3,4-噁二唑基团(例如,卤素)或从吡啶基团等组成的取代基的苯基团;所述杂环基可能具有至少一个从较低烷氧基等选择的取代基或其盐。
  • [EN] CEPHEM COMPOUNDS<br/>[FR] CEPHEMES
    申请人:FUJISAWA PHARMACEUTICAL CO
    公开号:WO2005027909A1
    公开(公告)日:2005-03-31
    The present invention relates to a compound of the formula [I]: wherein R1 is lower alkyl or hydroxy (lower) alkyl, and R2 is hydrogen or amino protecting group, or R1 and R2 are bonded together and form lower alkylene ; R3 is -A-R6 wherein A is bond, -NHCO-(CH2CO)n-, lower alkylene, -NH-CO-CO- or the like, and R6 is (a) ou (b) wherein R7, R8, R9 and R10 are independently amino, guanidino, amidino or the like ; R4 is carboxy or protected carboxy; and R5 is amino or protected amino, or a pharmaceutically acceptable salt thereof, a process for preparing a compound of the formula [I], and a pharmaceutical composition comprising a compound of the formula [I] in admixture with a pharmaceutically acceptable carrier.
    本发明涉及一种公式的化合物[I]:其中R1是低级烷基或羟基(低级)烷基,R2是氢或氨基保护基团,或者R1和R2连接并形成低级亚烷基;R3是-A-R6,其中A是键,-NHCO-(CH2CO)n-,低级亚烷基,-NH-CO-CO-或类似物质,R6是(a)或(b)其中R7,R8,R9和R10是独立的氨基,胍基,脒基或类似物质;R4是羧基或受保护的羧基;R5是氨基或受保护的氨基,或药用可接受的盐,一种制备公式化合物[I]的方法,以及一种包括与药用可接受载体混合的公式化合物[I]的药物组合物。
  • IMIDAZOPYRIDINE COMPOUNDS
    申请人:Iwata Hidehisa
    公开号:US20100069431A1
    公开(公告)日:2010-03-18
    Compounds, pharmaceutical compositions, kits and methods are provided for use with glucokinase that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein.
    提供了用于与葡萄糖激酶一起使用的化合物、药物组合物、试剂盒和方法,其中包括从以下公式(I)所述的组中选择的化合物,其中变量如本文所定义。
  • Benzamide compounds as apo b secretion inhibitors
    申请人:——
    公开号:US20040058903A1
    公开(公告)日:2004-03-25
    The present invention relates to compounds of the formula (I) wherein R 1 and R 2 are each independently lower alkyl lower alkenyl, acyl, amino, lower alkoxy, lower cycloalkyloxy, aryl, aryloxy, sulfooxy, mercapto, sulfo, hydrogen, halogen, nitro, cyano or hydroxy, or may form a ring structure; Q 1 is N or CH; L is optionally substituted unsaturated 3 to 10-membered heterocyclic group; X is optionally substituted monocyclic arylene or monocyclic heteroarylene; Y is -(A 1 ) m -(A 2 ) n -(A 4 ) k -; Z is directbond, —CH2-, —NH— or —O—; and R is hydrogen or lower alkyl, or a salt thereof The compounds of the present invention inhibit apolipoprotein B (Apo B) secretion and are useful as a medicament for prophylactic and treatment of diseases or conditions resulting from elevated circulating levels of Apo B.
    本发明涉及式(I)的化合物,其中R1和R2分别独立地为较低的烷基较低的烯基、酰基、氨基、较低的烷氧基、较低的环烷氧基、芳基、芳氧基、磺氧基、巯基、磺基、氢、卤素、硝基、氰基或羟基,或者可以形成环结构;Q1为N或CH;L是可选的取代的不饱和的3到10元杂环基;X是可选的取代的单环芳基或单环杂芳基;Y是-(A1)m-(A2)n-(A4)k-;Z是直键,-CH2-,-NH-或-O-;R为氢或较低的烷基,或其盐。本发明的化合物抑制载脂蛋白B(Apo B)的分泌,并可用作预防和治疗由于载脂蛋白B循环水平升高而导致的疾病或症状的药物。
  • [EN] BENZAZEPINE DERIVATIVES<br/>[FR] DÉRIVÉS DE BENZAZÉPINE
    申请人:OTSUKA PHARMA CO LTD
    公开号:WO2019004421A1
    公开(公告)日:2019-01-03
    The present invention provides novel benzazepine compounds of Formula (1), or salts thereof, having vasopressin V1a and V2 antagonisms, and medical uses thereof. In the formula, R1 is optionally substituted C1-6 alkyl, etc.; L is -C(=O)-NH-, etc.; Ring A1 is a hydrocarbon ring, etc.; Ring A2 is a hydrocarbon ring, etc.; and each of Rings A1 and A2 may have at least one substituent.
    本发明提供了具有抗利尿激素V1a和V2拮抗作用的新型苯并哌啶化合物的结构式(1)或其盐,以及其医药用途。在该式中,R1是可选取代的C1-6烷基等;L是-C(=O)-NH-等;环A1是一个碳氢环等;环A2是一个碳氢环等;环A1和环A2中的每一个可能具有至少一个取代基。
查看更多